HCPLive Five at AAD 2024

Published on: 

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This edition shares 5 important updates from the American Academy of Dermatology (AAD) 2024 meeting.

Counting down the biggest news from major medical meetings, it's the HCPLive Five!

This year’s American Academy of Dermatology (AAD) Annual Meeting featured a wide array of late-breaking data, important findings, and presentations on many topics in the quickly evolving field of dermatology.

The sunny locale of San Diego, California was the perfect location to inspire dermatologists from all corners of the country to converge and discuss the major trends in the field. On-site at AAD 2024, the HCPLive editorial team had the opportunity to interview several key opinion leaders on their teams’ late-breaking data, new treatment developments, and the seemingly daily changes in the field.

These interviews included coverage of potential benzene risk with benzoyl peroxide, with perspectives from acne and rosacea specialist James Q. Del Rosso, DO, and a discussion of the efficacy of at-home phototherapy compared to in-office administration for psoriasis patients from the LITE study, presented by Joel Gelfand, MD, MSCE. We also covered the phase 2 KNOCKOUT study findings which showed the efficacy of a high-dose, brief regimen of risankizumab for psoriasis, as covered by author Andrew Blauvelt, MD, MBA.

Additionally, the editorial team spoke with Andrew Alexis, MD, MPH, on his team’s interim findings from the ADmirable phase 3b study, the results of which highlighted lebrikizumab’s efficacy among adults and adolescents with skin of color and atopic dermatitis. The team also spoke with Alexa Kimball, MD, MPH, on the efficacy of lutikizumab in treating symptoms of moderate-to-severe hidradenitis suppurativa (HS) among adult nonresponders to anti-TNF therapy.

Check out our full coverage on our conference coverage page for AAD 2024.